Heybike
Heybike Launches V1 Pro, a 72V Power Beast with 8,000W Peak Power and Bigger Attitude
Heybike today announced the launch of the V1 Pro, a 72V electric dirt bike designed for riders who want bigger tires, bigger attitude, and ultimate…
Source
From PR Newswire
449 releases originally issued via PR Newswire. The issuing organizations are responsible for their content.
Ailytics
Tin Men Capital leads US$7.4M Series A for Vision AI startup Ailytics to expand across APAC, US and Gulf
Ailytics, a vision AI startup that turns existing industrial CCTV into a real-time safety and operations layer, has raised US$7.4 million in a Series…
LG Electronics, Inc.
LG ELECTRONICS ACCELERATES COMMERCIAL LAUNDRY GROWTH IN EUROPE AT EXPODETERGO INTERNATIONAL 2026
Full Commercial Laundry Lineup and Connected Management Solutions Advance LG's European B2B Expansion News Summary LG Electronics is showcasing a…
TECNO
Beyond the Label of Solo Motherhood: TECNO and Angélica Dass Launch the Philippines Portrait Gallery for 100 Portraits of Becoming
The gallery brings together 20 Filipinos whose lives intersect with solo motherhood, revealing the diverse roles, relationships and ambitions that…
FF EAI Robotics Ecosystem Inc.
FFR to Hold Listing Ceremony and Investor Day on October 26; FFAI Announces Rescheduling of YT Jia's Investor Weekly Report to October 26
Faraday Future announced that this week's Investor Weekly Report from FF Founder and Global CEO YT Jia has been rescheduled to October 26. FF EAI…
CARsgen Therapeutics
Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026
CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, announces that the…
Ascletis Pharma Inc.
Ascletis Announces FDA IND Submission of ASC39, an Oral Small Molecule Selective Amylin Receptor Agonist for the Treatment of Obesity
- ASC39, an oral small molecule selective amylin receptor agonist, demonstrated eloralintide-like amylin selectivity and efficacy in preclinical…
Elsevier Limited
OASE+ and Elsevier Agree Next-Phase Read and Publish Agreement to Expand Open Access Publishing in Japan
A new three-year term removes the annual cap on open access publishing under the Read and Publish agreement and extends eligibility beyond…
Innovent Biologics
2026 ESMO | Innovent Presents Multiple Clinical Data Updates for IBI363/TAK-928, a PD-1/Alpha-Biased IL-2 Bispecific Fusion Protein
The data showcased are from three Phase 1b clinical studies of IBI363/TAK-928 in first-line NSCLC, first-line G/GEJA, and immunotherapy-resistant…
RIMAN
RIMAN Connects Global Direct Selling Leaders with K-Beauty Innovation Through WFDSA World Congress and Jeju Experience Tour
RIMAN participated as a Platinum Sponsor of the 18th WFDSA World Congress, highlighting its proprietary ingredients and R&D capabilities The company…
Antengene Corporation Limited
Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering,…
FacePlus Plastic Surgery Institute
Lubbock Plastic Surgeon Dr. Thanapoom Boonipat Leads Suturing Workshop for Texas Tech Women in STEM Premed Students
Dr. Thanapoom "Mo" Boonipat, plastic surgeon and founder of FacePlus Plastic Surgery Institute in Lubbock, led a hands-on suturing workshop and…
Akeso, Inc.
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational…
Johnson & Johnson
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO…
Blumenthal Nordrehaug Bhowmik De Blouw LLP
Employment & Labor Lawyers, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Lawsuit Against Sinclair Television of California, LLC, for Alleged Failure to Provide Meal Periods and Rest Breaks
Allegedly, Sinclair Television of California, LLC failed to provide employees with accurate itemized wage statements due to missed meal breaks. This,…
Kelun-Biotech
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65;…
Kelun-Biotech
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of…
ExpertConsumers.org
Best AI Tools for Small Business Marketing (2026): CapCut Featured for Creating Professional Video and Visual Content by Expert Consumers
Expert Consumers has recognized CapCut in its 2026 coverage of the best AI tools for small business marketing, highlighting the platform's collection…
Consumer365.org
Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
Consumer365 has recognized TORRAS in its review of the best iPhone cases for 2026, highlighting the Ostand Q3 Air and Ostand Q3 Air Pro as two…
Eli Lilly and Company
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy…